Stable CAD (Coronary artery disease)

Here you will find all the latest content on stable coronary artery disease (stable CAD) published on this website. Results are listed in chronological order.

A complex and changing disease state requiring wide expertise, stable CAD can involve a diverse range of underlying chronic or evolutionary stages involving full use of all available tools, devices and techniques like those for invasive imaging and functional assessment. Taking into account underlying comorbidities such as diabetes is critical. Advances in imaging techniques, as well as the use of adjunctive pharmacotherapy, vascular access or invasive interventions such as bypass surgery, are important, as are understanding bleeding risks, all of which can be found here…

Filtered By
Stable CAD

230 results

2017 ESC Focused update on Dual Antiplatelet Therapy (DAPT)

04 Sep 2017

As dual antiplatelet therapy (DAPT) seems to have been interventionalists’ close companion since the pioneering studies showing its benefits over oral anticoagulants (OAC) some 20 years ago, the myriad of ensuing studies has led to expanding indications, but has also uncovered the inherent risks of DAPT. In the 2017 Focused Update, the hitherto accumulated evidence is eloquently summarized into a set of recommendations that provide guidance on some of the important questions of an interventional cardiologist's everyday practice: which of the currently available P2Y12 inhibitors should be selected, what is the optimal duration of DAPT and how to manage bleeding complications.

Dejan Milasinovic


Dejan Milasinovic

Ticagrelor or clopidogrel in DAPT for acute coronary syndromes: A call for a stepwise approach?

Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study

28 Aug 2017

Christopher Cook


Christopher Cook

How intravascular imaging can optimise PCI results

21 Aug 2017 - From EUROPCR 2017

Complex PCI, STEMI...does using IVUS really reduce major adverse cardiovascular events? Join C. Cook, Z. Ali and G. Guagliumi as they review the proper way to use this “irrefutable” imaging tool. Does IVUS have a role throughout a procedure? How should you prepare and map your strategy in advance? Leanr why they characterise this as “the essence of decision–making”? What does the future hold in store for these technologies? How can we move to more “objective” measurements? What is the importance of the upcoming trial comparing high-risk patients and high-risk lesion randomised to angiography against OCT? Learn more here…

Management of patients with multilevel atherosclerosis

11 Jul 2017 - From EUROPCR 2017

While we are used to treating coronary artery disease, interventional cardiologists need to keep in mind that many of these patients have a silent form of vascular involvement because of atherosclerosis. S. Redwood, F. Ribichini and M. Roffi focus on this complex topic and the implications of taking charge of patients with diffuse disease. What current evidence exists in this often older and sicker population? On what level should management begin? Why is the best treatment one that is provided by a clinician working with a team of dedicated specialists in a “patient-centred” approach? Learn the details here…

LIVE case: CAD in TAVI patient

From EUROPCR 2017

Consult this LIVE case on CAD in TAVI patient, an 87-year-old female patient with CAD and aortic stenosis that include a LIVE demonstration from Saint Thomas' Hospital, London.

Clinical case

A 87-year-old female with CAD and aortic stenosis:

Randomised to ACTIVATION trialSimplified TAVISapien 3 implanted
Dr Bernard Prendergast


Bernard Prendergast
Dr. Simon Redwood


Simon Redwood
Jane Hancock


Jane Hancock

Will PIONEER AF-PCI change my practice?

19 May 2017 – From EuroPCR 2017

EuroPCR 2017: Fresh data on OCT management, FFR guidance and bioresorbable stents

Participants saw exciting results from a number of late-breaking trials during EuroPCR 2017, focusing on such topics as chronic total occlusions (CTO), neurological outcomes following TAVI in intermediate-risk patients, and bioresorbable vs. bare metal stents.

New frontiers for coronay physiology

18 May 2017 – From EuroPCR 2017

Antiplatelet regimen after PCI: an ongoing debate

18 May 2017 – From EuroPCR 2017